M&A / Acquisition · MENA · Announced 19 Oct 2026
DKSH → NewBridge Pharmaceuticals
DKSH Healthcare's first platform-scale move outside Asia-Pacific. Debt-financed and set to close by end-Q1 2027, it turns a regional APAC distributor into a multi-regional commercial-outsourcing platform, with Saudi Arabia and the UAE as its anchor markets.
Parties: DKSH Holding AG (Switzerland) → NewBridge Pharmaceuticals (United Arab Emirates)
- Deal type
- M&A / Acquisition
- Value
- $390m
- Territory
- MENA — 14 markets (key: Saudi Arabia, UAE; + Egypt, Kuwait, Lebanon, Algeria, Morocco)
- Asset
- Acquisition of 100%
- Announced
- 19 Oct 2026
Our analysis
DKSH is acquiring 100% of NewBridge for a USD 390m EV , debt-financed, closing end-Q1 2027. It is DKSH Healthcare’s first platform-scale move beyond Asia-Pacific — converting a regional APAC distributor into a multi-regional commercial-outsourcing platform , and executing two stated DKSH priorities at once: shifting mix toward higher-value outsourcing, and accelerating M&A. NewBridge’s multinational team (CEO Joe Henein) joins DKSH
Download the full research brief
Our complete 10-section deal research brief covers the acquirer and target in depth, MENA market context, a five-test strategic rationale, full valuation and pro forma analysis, risk mapping, and a 100-day integration blueprint.
Source: EQS News